The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.
Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers
Open accessPublished version of a preprint
Abstract
Rapid development of antisense therapies can enable on-demand responses to new viral pathogens and make personalized medicine for genetic diseases practical. Antisense phosphorodiamidate morpholino oligomers (PMOs) are promising candidates to fill such a role, but their challenging synthesis limits their widespread application. To rapidly prototype potential PMO drug candidates, we report a fully automated flow-based oligonucleotide synthesizer. Our optimized synthesis platform reduces coupling times by up to 22-fold compared to previously reported methods. We demonstrate the power of our automated technology with the synthesis of milligram quantities of three candidate therapeutic PMO sequences for an unserved class of Duchenne muscular dystrophy (DMD). To further test our platform, we synthesize a PMO that targets the genomic mRNA of SARS-CoV-2 and demonstrate its antiviral effects. This platform could find broad application not only in designing new SARS-CoV-2 and DMD antisense therapeutics, but also for rapid development of PMO candidates to treat new and emerging diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0305-x · Cited by 1,343
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
SCHNölzer, M., ALEWOOD, P., JONES, A., ALEWOOD, D., & KENT, S. B. H. (1992) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1992.tb00291.x · Cited by 1,049
Automated Solid-Phase Synthesis of Oligosaccharides
Plante, O. J., Palmacci, E. R., & Seeberger, P. H. (2001) · Science · doi:10.1126/science.1057324 · Cited by 933
Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T. (2009) · Human Mutation · doi:10.1002/humu.20918 · Cited by 575
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
Xia, S., Yan, L., Xu, W., Agrawal, A. S., Algaissi, A., Tseng, C.-T. K., Wang, Q., Du, L., Tan, W., Wilson, I. A., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4580 · Cited by 501
Research works printed but not linked: 2
- Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020). · doi:10.1038/s41586-020-2639-4 · Paper page
- Summerton, J. E. & Weller, D. D. Uncharged morpholino-based polymers having phosphorous containing chiral intersubunit linkages. US patent 5,185,444 (1991).
Cited by
Chemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 172
Ma, W., Deng, Y., Xu, Z., Liu, X., Chapla, D. G., Moremen, K. W., Wen, L., & Li, T. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c01819 · Cited by 39
Automated Flow Synthesis of Peptide–PNA Conjugates
Li, C., Callahan, A. J., Phadke, K. S., Bellaire, B. H., Farquhar, C. E., Zhang, G., Schissel, C. K., Mijalis, A. J., Hartrampf, N., Loas, A., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c01019 · Cited by 40
Self-citationAI for organic and polymer synthesis
Hong, X., Yang, Q., Liao, K., Pei, J., Chen, M., Mo, F., Lu, H., Zhang, W.-B., Zhou, H., Chen, J., et al. (2024) · Science China Chemistry · doi:10.1007/s11426-024-2072-4 · Cited by 45
Ferrazzano, L., Corbisiero, D., Tolomelli, A., & Cabri, W. (2023) · Green Chemistry · doi:10.1039/d2gc04547h · Cited by 38
Metadata
- Authors
- Li, C., Callahan, A. J., Simon, M. D., Totaro, K. A., Mijalis, A. J., Phadke, K.-S., Zhang, G., Hartrampf, N., Schissel, C. K., Zhou, M., Zong, H., Hanson, G. J., Loas, A., Pohl, N. L. B., Verhoeven, D. E., & Pentelute, B. L.
- Affiliations
- Massachusetts Institute of Technology (US)
- Iowa State University (US)
- University of Zurich (CH)
- Sarepta Therapeutics (United States) (US)
- Indiana University Bloomington (US)
- Broad Institute (US)
- Corresponding author
- Pentelute, Bradley L.
- ORCID
- Venue
- Nature Communications
- Published
- 2021-07-20
- Volume
- 12
- Issue
- 1
- Pages
- 4396-4396
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8292409
- OpenAlex
- W3090618517
- Cited by
- 57
- References
- 41
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 14 · 2023: 14 · 2022: 7 · 2021: 6
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- ChemRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Nature
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Koch Institute MIT School of Science Fellowship in Cancer Research
- Sarepta Therapeutics, Inc.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- phosphorodiamidate morpholino oligomers, antisense oligonucleotides, automated oligonucleotide synthesis, Duchenne muscular dystrophy, SARS-CoV-2, antiviral oligonucleotides, antisense therapeutics
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Animals, Chlorocebus aethiops, Chemistry, Pharmaceutical, Disease Models, Animal, Humans, RNA, Messenger, RNA, Viral, Time Factors, Vero Cells, Oligonucleotides, Antisense, Muscular Dystrophy, Duchenne, Communicable Diseases, Emerging, High-Throughput Screening Assays, Precision Medicine, Morpholinos, Chemistry Techniques, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers. https://app.cochat.ai/papers/10.1038/s41467-021-24598-4
- The paper
- Li, C., Callahan, A. J., Simon, M. D., Totaro, K. A., Mijalis, A. J., Phadke, K.-S., Zhang, G., Hartrampf, N., Schissel, C. K., Zhou, M., Zong, H., Hanson, G. J., Loas, A., Pohl, N. L. B., Verhoeven, D. E., & Pentelute, B. L. (2021). Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers. Nature Communications. https://doi.org/10.1038/s41467-021-24598-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.